REFERENCES/ BIBLIOGRAPHY

1. Abridged products (2011) Viewed 27 December 2011 <http :// www.mhra.gov.uk/ How we regulate/ Medicines/ Licensing of medicines/ Marketing authorisations / Abridged products/ index.htm>
2. Ahmed, D, El-Setouhy, Shawky, N, Abd El-Malak (2010 October 7). Formulation of a Novel Tianeptine Sodium Orodispersible Film, AAPS PharmSciTech.; 11(4): Pg. no.1499.
3. Aulton, M.E (2007), 'Dosage form Design & Manufacture', Aulton's Pharmaceutics. Third Edition, Edinburg London, Pg no. 518-520
4. Banker, G.S & Rhodes, C.T (2002), 'Hard & soft shell capsules', Modern Pharmaceutics. Fourth Edition, Marcel Dekker, Inc. New York, Pg. no 2
5. Bernard K, Penelaud PF, Mocaër E, Donazzolo Y. (2011 Aug). Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers, Journal of Clinical Psychopharmacology., 31(4), Pg. no.441-8.
6. Blackett,T. (1992). Branding and the Rise of the Generic Drug. Marketing Intelligence & Planning, Vol. 10, Issue : 9, Pg. no.21 – 24.
7. Blanchard, J., Turbe, H., Brigot, D.(2002), Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepine and application to the synthesis of tianeptine, US Patent 6441165
8. Boiret M, Meunier L, Ginot YM. (2011 Feb 20). Tablet potency of Tianeptine in coated tablets by near infrared spectroscopy: model optimisation, calibration transfer and confidence intervals. Journal of Pharmaceutical Biomedical Analysis. 54(3), Pg no.510-6.
9. Brink, C.B, Harvey, B.H, and Brand .L (2006). Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression, Recent Patents on CNS Drug Discovery, Vol. 1, No. 1, Pg. no.29-41.
10. Brooks, C.W. (2004,August). An overview of Non infringement opinion.Michigan Bar Journal, Pg. no. 24-26.
11. Bruno, H. De B, Patrick, W. (1997). Matrix-type oral sustained-release tablets containing tianeptine sodium salt, EP0803253 (A1) — 1997-10-29.

12. Cartwright & Anthony C. (2006). The Electronic Common Technical Document: From Design to Submission. International Journal of Pharmaceutical Medicine, Volume 20, Issue 3, Pg no. 149-158
13. European Pharmacopoeia Commission (2005): European Pharmacopoeia. Volume 2, 5th Edition. Strasbourg. Council of Europe. Pg no. 2575-76.
14. Guzman, H et al.,(2010), Tianeptine sulfate salt forms and methods of making and using the same, WIPO Patent 2010051239.
15. Hardman JG, Limbird LE (eds) (2001), 'Drugs acting on the Central Nervous System, Goodman and Gilman's The Pharmacological Basis of Therapeutics. Tenth edition, McGraw-Hill: New York, Pg no.474
16. Khedr, A (Jul-2007). High-Performance Liquid Chromatographic Stability Indicating Assay Method of Tianeptine Sodium with Simultaneous Fluorescence and UV Detection, Journal of Chromatographic Science, Volume 45, Page No. 305-310.
17. Kucharik, R.F., Harris, H.W. (2004), Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia,US Patent 6683072, Vela Pharmaceuticals, Inc.
18. Lachman, L., Liberman, H.A., Kanig, J.L. (1990), 'Capsules', The Theory and Practice of Industrial. Pharmacy. 3rd edition; Verghese publishing House, Mumbai, Pg no. 374-386.
19. M4 : The Common Technical Document (2003, July) Viewed 20 December 2011< http://www.ich.org/products/ctd.html>
20. Mathur.V. & Nagori.B.P. (2008, November). Patent Opinions and their Role in Developing Generic Medicines: A US Perspective. Journal of Generic Medicines, Vol. 6, Pg no. 29-34.
21. McEwen, B.S, Magarinos, A.M, Reagan, L.P.(2002 Jul;17). Structural plasticity and tianeptine: cellular and molecular targets, European Psychiatry Suppl 3: Pg. no.318-30.
22. Medicines and Healthcare products Regulatory Agency (MHRA)(2011 December;02) Viewed 30 December 2011<http://www.mhra.gov.uk/Aboutus /index.htm>
23. MIMS Singapore (2011) Viewed 11 December 2011 < http://www.mims. com/ Singapore/drug/info/Stablon/Stablon%20tab?type=full>

24. Molzon.J. (2003, January). Common Technical Document: the changing face of the New Drug Application. Nature Reviews Drug Discovery 2, Pg. no.71-74
25. Nagori.B.P & Mathur.V. (2009, January). Basics of writing Patent Non-infringement & freedom-to- operate opinions. Journal of Intellectual property right, Volume 14, Pg no. 7-13
26. Nally, J.D (1998), 'Packaging & Labeling control', Good Manufacturing Practice for Pharmaceuticals. Sixth edition, Informa Healthcare New York, London, Pg no. 142-144.
27. Nickel, Thomas MD; Sonntag, Annette MD et al (April 2003). Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression. Journal of Clinical Psychopharmacology, Volume 23 - Issue 2 , Pg. no. 155-168
28. Piero Del Soldato et al (2007), Drugs for chronic pains, US patent 7199141.
29. Proença P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN.(2007 Aug 6). Fatal intoxication with tianeptine (Stablon), Forensic Science International.; 170 (2-3): Pg. no. 200-3.
30. Roegel, J.C, Eftekhari, P.(2009), Novel Uses for Drugs Targeting Glutamine Synthetase US Patent 0209474 A1.
31. Sharma,P.C, Kumar,S., Pahwa, R & Sharma, A (2009).Opportunities for Generic Drugs in India. The Internet Journal of Third World Medicine, Volume 8 Number 1
32. Suchanek .A & Ostermann.H (2012, 25 January). The Electronic Common Technical Document (eCTD): An International Pro/Con Analysis of the Pharmaceutical Product Electronic Submission Process. Drug Information Journal, Vol.46, no.1, Pg. no. 124-139
33. The Value and Benefits of ICH to Drug Regulatory Authorities (2010) viewed 10 December 2011 <http://www.ich.org/fileadmin/Public_Web_Site/News_room/ C _Publications/ICH_20_anniversary_Value_Benefits_of_ICH_for_Regulators.pdf>
34. Tripathi, K.D. (2004), 'Antidepressant Drugs', Essentials of Medical Pharmacology. 5th edition, Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, Pg. no. 413.
35. Ulu ST, Aydogmus Z. (2008 Dec). A new spectrophotometric method for the determination of tianeptine in tablets using ion-pair reagents. Chemical & Pharmaceutical Bulletin (Tokyo), 56(12), Pg. no.1635-8.

36. Vuković O, Marić NP, Britvić D, Cvetić T, Damjanović A, Prostran M, Jasović-Gasić M.(2009, Jun). Efficacy, tolerability and safety of tianeptine in special populations of depressive patients, Psychiatria Danubina.; 21(2):Pg. no.194-8
37. Wagstaff , A.J, Ormrod D, Spencer C.M (2001). Tianeptine: a review of its use in depressive disorders, CNS Drugs; 15(3): Pg. No.231-59.
38. Wilde MI; Benfield P ,Defrance R, Marey C, Kamoun A,(1988), Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials, Institut de Recherches Internationales Servier, Neuilly – sur - Seine, France., Clin Neuro-pharmacol; 11 Suppl 2: S74-82
39. Wilde, MI, Benfield, P. (1995 July).Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression, Adis International Limited, Auckland, New Zealand. Erratum in Drugs; 50(1):156.